| | Agent | Target | Type | Suggested indication | Clinical trials |
| | Milatuzumab | CD74 | Humanized | CLL, MM, NHL | (i) Phase I/II Study of Veltuzumab Combined with Milatuzumab in Relapsed and Refractory NHL
(ii) Phase I/II Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients with Relapsed NHL and CLL |
| | Apolizumab | HLA-DR beta | Humanized | CLL, NHL | No currently active clinical trials found |
| | Epratuzumab | CD22 | Humanized | NHL, ALL, WM | (i) Phase I/II Study of Veltuzumab Combined with 90Y-Epratuzumab Tetraxetan in Patients with Relapsed/Refractory, Aggressive NHL
(ii) International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010: A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group
(iii) Phase I/II Study Combining Humanised Anti-CD20 (Veltuzumab), Anti-CD22 (Epratuzumab) and Both Monoclonal Antibodies with Intensive Chemotherapy in Adults with Recurrent or Refractory B-Precursor ALL
(iv) Evaluation of the Efficacy and Tolerance of Fractionated Radio-immunotherapy with 90Y-Epratuzumab (90Y-hLL2) for Relapsed or Refractory CD22+ B-ALL |
| | Veltuzumab | CD20 | Humanized | NHL, ITP, CLL, ALL | (i) Phase I/II Study of Veltuzumab Combined with 90Y-Epratuzumab Tetraxetan in Patients with Relapsed/Refractory, Aggressive NHL
(ii) A Phase I/II Study of Veltuzumab (IMMU-106, hA20), a Humanized Anti-CD20 Monoclonal Antibody, Combined with Milatuzumab (IMMU-115, hLL1), a Humanized Anti-CD74 Monoclonal Antibody in Relapsed and Refractory B-Cell NHL
(iii) A Phase I/II Study of Immunotherapy with Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Adult Patients with Chronic ITP
(iv) Phase I/II Study Combining Humanised Anti-CD20 (Veltuzumab), Anti-CD22 (Epratuzumab) and Both Monoclonal Antibodies with Intensive Chemotherapy in Adults with Recurrent or Refractory B-Precursor ALL |
| | Lumiliximab | CD23 | Chimeric | CLL | No currently active clinical trials found |
| | Galiximab | CD80 | Chimeric | NHL | (i) A Phase II Study of Galiximab (Anti-CD80) for Patients with Relapsed/Refractory NHL
(ii) A Phase II Trial of Extended Induction Galiximab (Anti-CD80 Monoclonal Antibody) (IND #XXXXX) Plus Rituximab in Previously Untreated Follicular NHL |
| | Bevacizumab | VEGF | Humanized | MM, HL | (i) Phase II Trial of Bevacizumab Combined with Lenalidomide and Dexamethasone (BEV/REV/DEX) in Relapsed or Refractory MM
(ii) Avastin (Bevacizumab) in Combination with ABVD for the Treatment of Newly Diagnosed Advanced Stage Classical HL |
| | Obinutuzumab | CD20 | Humanized | CLL, NHL | (i) Open-Label, Multicenter, Three-Arm Randomized Study to Investigate the Safety and Efficacy on Progression-Free Survival of RO5072759 + Chlorambucil (GClb) Compared to Rituximab + Chlorambucil (RClb) or Chlorambucil (Clb) Alone in Previously Untreated CLL Patients with Comorbidities
(ii) Open-Label, Multicenter, Randomized Study to Evaluate the Efficacy on Tumor Response of GA101 (RO5072759) Monotherapy versus Rituximab Monotherapy in Patients with Relapsed CD20+ Indolent NHL
(iii) An Open-Label, Multicenter, Three-Arm Randomized Study to Investigate the Safety and Efficacy on Progression-Free Survival of RO5072759 + Chlorambucil (GClb) Compared to Rituximab + Chlorambucil (RClb) or Chlorambucil (Clb) Alone in Previously Untreated CLL Patients with Comorbidities
(iv) Multicenter Phase I/Ib Study Evaluating the Efficacy and Safety of TGR-1202, a Novel PI3K Delta Inhibitor, in Combination with Obinutuzumab and Chlorambucil in Patients with CLL
(v) A Multicenter Phase I/Ib Study Evaluating the Efficacy and Safety of TGR-1202, a Novel PI3K Delta Inhibitor, in Combination with Obinutuzumab and Chlorambucil in Patients with CLL
(vi) A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated CLL
(vii) A Phase 1b Open-Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Rituximab or in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia
(viii) A Phase Ib Study of the Safety and Pharmacology of MPDL3280A Administered with Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
(ix) A Phase I/II Study of Lenalidomide and Obinutuzumab (GA101) in Relapsed Indolent NHL
(x) A Multicenter, Open-Label, Single-Arm, Multiple Dose Study to Assess the Pharmacokinetics of RO5072759 in Chinese Patients with CD20+ Malignant Disease
(xi) An Open-Label, Multicentre, Randomized, Phase Ib Study to Investigate the Safety and Efficacy of RO5072759 Given in Combination with CHOP, FC or Bendamustine Chemotherapy in Patients with CD20+ B-Cell Follicular NHL
(xii) An Open-Label, Multicenter, Randomized Phase II Trial Comparing the Efficacy, Safety, and Pharmacokinetics of GA101 1000 mg versus 2000 mg in Patients with Previously Untreated CLL
(xiii) A Multicenter, Open-Label, Single-Arm, Phase IIIb International Study Evaluating the Safety of Obinutuzumab Alone or in Combination with Chemotherapy in Patients with Previously Untreated or Relapsed/Refractory CLL
(xiv) Phase II Trial to Evaluate The Efficacy of Obinutuzumab (RO5072759) + Bendamustine Treatment in Patients with Refractory Or Relapsed CLL
(xv) A Phase II, Open-Label, Multicenter Study of Efficacy, Safety, and Biomarkers in Patients with Previously Untreated Advanced DLBCL Treated with GA101 (RO5072759) in Combination with CHOP Chemotherapy
(xvi) A Phase IB/II Study of GA101 in Combination with High-Dose Methylprednisolone (HDMP) in CLL Patients
(xvii) A Phase Ib Multicenter Dose-Finding And Safety Study Of GDC-0199 and Obinutuzumab in Patients with Relapsed or Refractory or Previously Untreated CLL
(xviii) A Phase Ib/II Study of Obinutuzumab Combined to Lenalidomide for the Treatment of Relapsed/Refractory Follicular and Aggressive DLBCL and MCL B-Cell Lymphoma
(xix) A Phase III, Multicenter, Open-Label Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination with CHOP (G-CHOP) versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with CD20-Positive DLBCL
(xx) Phase II Randomized Trial Comparing GA101 (Obinutuzumab) and Rituximab in Patients with Previously Untreated Low Tumor Burden Indolent NHL
(xxi) A Multicentre, Phase III, Open-Label, Randomized Study in Previously Untreated Patients with Advanced Indolent NHL Evaluating the Benefit of GA101 (RO5072759) + Chemotherapy Compared to Rituximab + Chemotherapy followed by GA101 or Rituximab Maintenance Therapy in Responders
(xxii) An Open-Label, Multicenter, Phase Ib Trial of GA101 (RO5072759) in Combination with Chemotherapy in Patients with Previously Untreated CLL
(xxiii) A Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of GDC-0199 (ABT-199) in Combination with Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (Chop) in Patients with B-Cell NHL and DLBCL
(xxiv) An Open-Label, Multicenter, Randomized, Phase III Study to Investigate the Efficacy and Safety of Bendamustine Compared with Bendamustine+RO5072759 (GA101) in Patients with Rituximab-Refractory, Indolent NHL | | Dacetuzumab | CD40 | Humanized | NHL | No information |
| | Lintuzumab | CD33 | Humanized | AML, MDS, CML, APL | (i) A Phase I/II Study of Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients with Untreated AML
(ii) Phase I Trial of Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients with Advanced Myeloid Malignancies |
|
|
